BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases

Breast cancer is the second most common cancer in Sweden with an incidence of 8000 per year. The role of surgery for distant breast cancer metastasis beyond local lymph nodes remains controversial even though some reports suggest there might be a survival benefit from resection of oligometastases in the liver. The purpose of this multicentre randomized clinical trial is to evaluate local treatment for breast cancer liver metastases, compared to systemic oncological treatment only. The primary endpoint is time to death from any cause, which will be compared using cox proportional hazard regres

Trial Details

NCT ID
NCT04079049
Phase
PHASE3
Sponsor
Umeå University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Surgical intervention
  • Control
Locations (sample)
  • Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • Signed informed consent
  • \>18 years old
  • Breast cancer history
  • Breast cancer liver metastasis verified by biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →